TD Cowen raised the firm’s price target on Agilent (A) to $162 from $150 and keeps a Buy rating on the shares. The firm said they expect 2026 organic guidance of around 5% which is roughly in line with consensus, with EBIT expansion likely a bit below consensus at +70bp year-over-year, hence our F26 EPS is below consensus but with a good F4Q coming, Biopharma turning, idiosyncratic drivers and likely upside to F26 forecasts they reiterate their Buy rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Netflix, Veeva, AST SpaceMobile, Alphabet, Agilent: Trending by Analysts
- Agilent price target raised to $165 from $155 at JPMorgan
- Agilent initiated with a Buy at Rothschild & Co Redburn
- Agilent upgraded to Buy from Neutral at UBS
- Cautious Hold Rating for Agilent Amid New Product Launch and Market Uncertainties